What this means
This trial plans to test whether a supplement called CoQ10 plus hard exercise can improve energy in cells and physical strength. It has not reported results, so it does not yet show whether either helps.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18–75
- Where
- 2 sites, including California, Tennessee
The science
- Registered title
- CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
- Trial ID
- NCT05422534 ↗
- Phase
- PHASE 3
- Study type
- interventional
- Conditions
- End Stage Renal Disease
- What is tested
- CoQ10, Placebo, HB-HIIT, Observational
- Sponsor
- Vanderbilt University Medical Center
- Ages
- 18 Years to 75 Years
- Dates
- First posted Jun 16, 2022 · updated Jan 2, 2026
Registry summary
Frailty and sarcopenia are modifiable risk factors for morbidity and mortality in patients with ESRD. Exercise is the recommended intervention to prevent frailty and sarcopenia, however, many clinical trials have shown limited clinical improvement in muscle mass and physical function. We propose that mitochondrial dysfunction is one of the deterrents to the effectiveness of the exercise. We plan to evaluate the additive effect of HIIT and CoQ10, a mitochondrial-targeted therapy, on mitochondrial function and physical performance. Understanding the interplay among CoQ10, exercise, and mitochondrial function will identify novel mechanisms to improve the efficiency of exercise. This will also serve to prevent frailty, sarcopenia, and muscle dysfunction in patients with ESRD.
Sites (2)
- University of California Davis Health, Sacramento, California, United States
- Vanderbilt University Medical Center-GCRC, Nashville, Tennessee, United States